{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Section 9.1 Efficacy', 'Clarified language regarding collection', 'Language modified to allow for', 'Assessments', 'of PD blood sample', 'confirmation sample to occur on', 'the same day as original', 'collection.', 'Section 9.2 Adverse', 'Added clarity on use of GSK Scale and', 'Revised to provide clear', 'Events', 'CTCAE', 'guidance for dose modifications', 'due to GSK2857916 corneal', 'Added clarity that all AEs will be', 'events.', 'graded using CTCAE and that corneal', 'events will also be graded using the', 'CTCAE scale will be utilized to', 'GSK scale. GSK2857916 dosing', 'harmonize data with FTIH study', 'decisions related to GSK2857916', 'results', 'corneal events are to be made using', 'the GSK Scale for corneal events.', 'Section 9.2.1 Time', 'Updated AE reporting timeframe from', 'Revised to align with 5 half-lives', 'Period and Frequency', '30 days to 45 days', 'of GSK2857916', 'for collecting AE and', 'SAE information', 'Section 9.2.6 Disease', 'Clarified disease progression does not', 'Updated to align with GSK', 'Related Events and/or', 'need to be reported as an SAE', 'internal standards for oncology', 'Disease Related', 'trials.', 'Section 9.2.7 Adverse', 'Added that corneal AESI should be', 'Revised to align with Section', 'Events of Special', 'graded by CTCAE and GSK Scale for', '9.2 Adverse Events.', 'Interest', 'corneal events', 'Section 9.2.9 Ocular', 'Added statement to clarify', 'Revised to align with all', 'Exams and Procedures', 'representative images will be collected', 'GSK2857916 protocols', 'and stored centrally.', 'Section 9.2.10.1', 'Preservative free artificial tear', 'Clarification to align with Table', 'Monocular Prophylaxis', 'requirements updated to align with', '21.', 'Table 21, Prophylactic measures for', 'corneal events associated with', 'GSK2857916', 'Section 9.2.10.3 Sub-', 'Clarification of exam requirements', 'Updated information regarding', 'Study Exams', 'confocal exams.', 'Section 9.4.2 ECOG', 'Timepoints updated to perform to align', 'Clarification to align with', 'Performance Status', 'with Section 2, Schedule of Activities', 'Section 2.', 'Section 9.4.4', 'Triplicate ECG measurements changed', 'Allows time for EOI PK sample', '141']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Section # and Name', 'Description of Change', 'Brief Rationale', 'Electrocardiogram', 'to 2 minutes apart', 'collection', 'Section 10.2 Sample', 'Update the type-1 error and power due', \"To address EMA's comments\", 'Size Determination', 'to the change in boundary for claiming', 'on maintaining overall type-1', 'efficacy at final ORR analysis.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', 'efficacy at final ORR analysis', 'was modified.', 'Section 10.3 Sample', 'Update scenarios due to change in', \"To address EMA's comments\", 'Size Sensitivity', 'boundary for claiming efficacy at final', 'on maintaining overall type-1', 'ORR analysis.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', 'efficacy at final ORR analysis', 'was modified.', 'Section 10.4', 'Provide reference for detailed definition', 'To ensure consistency with', 'Populations for Analysis', 'of Evaluable Population, which will be', 'IDMC charter', 'used for ORR analysis at interim', 'Section 10.5.1 Efficacy', 'Update language regarding ORR', 'Clarify that the ORR analysis at', 'Analyses', '(confirmed VS. unconfirmed) at interim', 'interim should be based on', 'analysis.', 'confirmed response if available.', 'Section 10.5.2 Safety', 'Addition of summarizing corneal events', 'To clarify that AESI of corneal', 'Analysis', 'using GSK Scale for corneal events', 'events will also be summarized', 'Table 18', 'using the GSK Scale for corneal', 'events.', 'Section', 'Creation of subsections in Section', 'For clarity', '10.5.4. 1Pharmacokinetic', '10.5.4 to separate pharmacokinetic', 'Added noncompartmental', 'Data Analyses', 'and statistical analyses', 'analysis based on revised PK', 'Addition of non-compartmental', 'sampling schedule', 'analysis, data permitting', 'Section 10.5.4.2', 'Creation of subsections in Section', 'For clarity', 'Statistical Analysis of', '10.5.4 to separate pharmacokinetic', 'Pharmacokinetic Data', 'and statistical analyses', 'Section 10.5.9 Interim', 'Modify boundary of claiming efficacy at', \"To address EMA's comments\", 'Analyses', 'final ORR analysis, and associated', 'on maintaining overall type-1', 'operating characteristics.', 'error (1-sided 2.5%) adjusting', 'for multiplicity (two dose arms),', 'the boundary for claiming', '142']\n\n###\n\n", "completion": "END"}